FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer By Ogkologos - July 11, 2025 469 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Lung05 and TROPION-Lung01 studies Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Tislelizumab June 7, 2024 Pediatric MATCH Study Finds More Targetable Genetic Changes than Expected May 16, 2019 Foodie Fridays: An Ode to Summer Tomatoes July 2, 2021 Does Sugar Feed Cancer? March 19, 2021 Load more HOT NEWS Hospice Service Provides “Bucket List” Tattoo for 77-Year-Old Woman with Breast... FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle... Stressed out – the cancer cells that survive chemotherapy, but at... Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of...
